Haemophilia : the official journal of the World Federation of Hemophilia
Integration of Efanesoctocog Alfa in Clinical Practice for Children, Adolescents, and Young Adults With Severe Haemophilia A.
Debbie Jiang, Natalie Johnston, Daniel Echelman, Stacy E Croteau
Published: 202510.1111/hae.70175
Abstract
INTRODUCTION: Efanesoctocog alfa is a novel, "ultra-extended half-life" FVIII concentrate for bleed treatment and prevention in haemophilia A. Clinical trials excluded individuals with active or prior FVIII inhibitors, those on emicizumab, and previo…
Preview only. Read the full abstract at the source